Value of the US BI-RADS final assessment following mastectomy: BI-RADS 4 and 5 lesions by �젙吏� et al.
 http://acr.sagepub.com/
Acta Radiologica
 http://acr.sagepub.com/content/53/3/255
The online version of this article can be found at:
 
DOI: 10.1258/ar.2011.110597
 2012 53: 255Acta Radiol
Hye Mi Gweon, Eun Ju Son, Ji Hyun Youk, Jeong-Ah Kim and Jin Chung
Value of the US BI-RADS final assessment following mastectomy: BI-RADS 4 and 5 lesions
 
 
Published by:
 http://www.sagepublications.com
On behalf of:
 
 Nordic Society of Medical Radiology
 can be found at:Acta RadiologicaAdditional services and information for 
 
 
 
 
 http://acr.sagepub.com/cgi/alertsEmail Alerts: 
 
 http://acr.sagepub.com/subscriptionsSubscriptions:  
 http://www.sagepub.com/journalsReprints.navReprints: 
 
 http://www.sagepub.com/journalsPermissions.navPermissions: 
 
 What is This?
 
- Apr 1, 2012Version of Record >> 
 at International Relations on June 17, 2013acr.sagepub.comDownloaded from 
Original article
Value of the US BI-RADS final assessment following
mastectomy: BI-RADS 4 and 5 lesions
Hye Mi Gweon, Eun Ju Son, Ji Hyun Youk, Jeong-Ah Kim and Jin Chung
Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
Correspondence to: Eun Ju Son. Email: ejsonrd@yuhs.ac
Abstract
Background: Clinical examination is not entirely sufficient for evaluation of the postoperative site for follow-
up of patients with mastectomy. A few studies have reported that postoperative follow-up US evaluation
allows early detection and proper management of local tumor recurrence.
Purpose: To evaluate the diagnostic performance of the American College of Radiology (ACR)
ultrasonographic (US) Breast Imaging Reporting and Data System (BI-RADS) categories 4 and 5 breast
lesions at the mastectomy site.
Material and Methods: Our institutional review board approved this study and waived the need for informed
consent. We retrospectively reviewed the consecutive post-mastectomy US exams for palpable and
non-palpable lesions in the post-mastectomy chest wall that were categorized as BI-RADS 4
(subcategorized 4a, 4b, and 4c) or 5 between January 2007 and April 2010. The positive predictive value
(PPV) for final assessment was evaluated.
Results: From 2681 post-mastectomy US examinations, we obtained a study population of 50 patients with
50 lesions (20 palpable, 30 non-palpable). There were nine (45%) malignancies among the palpable lesions
and six (20%) malignancies among the non-palpable lesions. The palpability showed no significant
correlation with malignancy in overall subcategorization (P .0.05). The PPVs of categories 4 and 5 were
14.3% for category 4a, 62.5% for category 4b, 100% for category 4c, and 100% for category 5.
Conclusion: The ACR US BI-RADS categorization of 4a, 4b, 4c, and 5 for breast lesions at the mastectomy
site is a feasible method for predicting local recurrence. All lesions should be managed according to US
characteristics during evaluation of local recurrence at the mastectomy site, regardless of palpability.
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Early diagnosis and a combination of surgery, chemotherapy,
and radiation therapy have led to a substantial decrease in
breast cancer-related mortality and improved survival (1).
However, local recurrence and distant metastasis remain
a major problem in breast cancer management. Patients
with local recurrence as a ﬁrst site of failure are at higher
risk for subsequent distant relapse than patients who are
free of local recurrence, leading to lower survival (2–5).
Clinical examination is mandatory but not entirely sufﬁ-
cient for evaluation of the postoperative site for follow-up
of patients with mastectomy. Ultrasound (US) evaluation
of the chest wall is not routinely performed in the follow-up
after mastectomy. A few studies have reported that post-
operative follow-up US evaluation allows early detection
and proper management of local tumor recurrence (6–8).
To our knowledge, however, no studies have assessed the
diagnostic accuracy of postmastectomy US according to
the American College of Radiology (ACR) US Breast
Imaging Reporting and Data System (BI-RADS) (9).
Therefore, the purpose of our study was to evaluate the
diagnostic performances of US BI-RADS categories for
evaluation of chest wall lesions after mastectomy.
Material and Methods
Surveillance protocol and study population
At our institution, clinical examination after breast cancer
surgery is performed by a surgeon every 6 months for the
ﬁrst 2 or 3 years and annually thereafter. In addition, all
patients with a history of surgery for breast cancer are
advised to undergo postoperative breast US every 6
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months, along with annual mammography for the ﬁrst 2 or
3 years after surgery and annual breast US and mammogra-
phy thereafter. Also, our clinicians request US whenever a
new palpable mass is detected.
Our institutional review board approved our retrospec-
tive study and waived the informed consent requirement.
After review of the database, we collected 2681 consecutive
US exams for chest wall after mastectomy (unilateral n ¼
2599; bilateral n ¼ 82) performed between January 2007
and April 2010. Among these, we selected chest wall
lesions assigned a BI-RADS ﬁnal assessment category 4 or
5 at US. Chest wall lesions assigned to BI-RADS category
1, 2, or 3 or contralateral breast lesions assigned to
BI-RADS category 4 or 5 were not included in this study.
Chest wall lesions assigned to BI-RADS category 4 or 5
that were not conﬁrmed pathologically were also excluded.
Imaging studies and interpretation
US examination was performed with 7-12 MHz linear-array
transducers (iU22 or HDI 5000, Philips-Advanced
Technology Laboratories, Bothell, WA, USA) by one of
three full-time, board-certiﬁed radiologists (authors HMG,
EJS, JHY, who have 2, 11, and 5 years of experience with
breast US, respectively). The radiologist performing the US
had information of the patient’s history and physical exam-
ination results from the clinician. When patients noted palp-
able lesions, the radiologists checked the lesions by means
of a physical examination and US. The breast areas, chest
walls, and bilateral axillary lymph node areas were routi-
nely scanned. The lesion images were acquired in both the
transverse and longitudinal projections with and without
caliper measurement. The lesion size was measured in the
maximal dimension.
ACR BI-RADS lexicon and ﬁnal assessment were used in
the radiologic interpretation. All lesions with low, inter-
mediate, or moderate suspicion for malignancy were cate-
gorized as BI-RADS 4a, 4b, or 4c, respectively. Lesions
categorized as BI-RADS 5 were considered to be highly sug-
gestive of malignancy. Based on previous studies (10–12),
suspicious ﬁndings were divided into major and minor,
where major signs included irregular shape, spiculated
margin, and microcalciﬁcation, and minor signs included
round shape, microlobulated/indistinct/angular margins,
non-parallel orientation, complex echogenicity, and pos-
terior shadowing. BI-RADS category 4a was deﬁned for
lesions with one or more minor suspicious ﬁndings, cat-
egory 4b for lesions showing more than three minor suspi-
cious ﬁndings, and category 4c for lesions with one major
suspicious ﬁnding with or without a minor suspicious
ﬁnding. Category 5 lesions were deﬁned for lesions
showing two or more major suspicious ﬁndings.
US-guided ﬁne-needle aspiration biopsy (FNAB) or spring-
loaded core needle biopsy (CNB) was recommended for all
lesions categorized as BI-RADS 4 or 5.
US-guided FNAB or CNB
Three radiologists were randomly assigned to each patient
for US-guided FNAB or CNB. US-guided FNAB was
performed at least twice using a 23-gauge needle (mean
passage 2.3; range 2–3). US-guided CNB was performed
using a freehand technique, and each procedure was per-
formed with a 14- or 18-gauge dual-action semi-automatic
core biopsy needle (Stericut with coaxial; TSK Laboratory,
Tochigi, Japan). The throw of the biopsy needle was
2.2 cm. Our standard protocol included four or ﬁve core
samples per lesion.
Data and statistical analysis
The ﬁnal diagnosis was based on pathologic results and
clinical and imaging follow-up results from at least 12
months after the detection of lesion at mastectomy site. A
positive for malignancy at FNAB or CNB examination was
deﬁned as a pathologic malignancy result. A negative for
malignancy at FNAB or CNB examination was deﬁned as
no evidence of recurrence during follow-up for at least 12
months.
Diagnostic indexes such as positive predictive value
(PPV) of US BI-RADS category for mastectomy site were cal-
culated. Also, the PPVs were compared between palpable
and non-palpable lesions. Statistical signiﬁcance was
assigned using a x2 test with statistical software (SPSS 18.0
for Windows; SPSS, Chicago, IL, USA). A P value of less
than 0.05 was considered to indicate statistical signiﬁcance.
Results
Diagnostic performance of BI-RADS category in US
for mastectomy site
Of 2681 US examinations, 50 lesions (1.8%) in 50 patients
(mean age 52 years, range 39–70 years) were categorized
as BI-RADS 4 or 5. The sizes of the 50 lesions ranged from
3 to 28 mm (mean 10.2 mm). The assigned BI-RADS ﬁnal
assessment category of the 50 chest wall lesions was cat-
egory 4a in 35 (70%), category 4b in eight (16%), category
4c in three (6%), and category 5 in four (8%). After
US-guided FNAB (n ¼ 22) or CNB (n ¼ 28), 15 (30%) were
diagnosed as malignant and 35 (70%) as benign. Table 1
summarizes the biopsy results and PPVs of each US
BI-RADS category for chest wall lesions. Regarding
palpability, 20 (40%) were palpable and 30 (60%) were
non-palpable. There were nine (45%) malignancies in the
palpable lesions and six (20%) malignancies in the
non-palpable lesions (P . 0.05). The palpability showed
no signiﬁcant correlation with malignancy in overall sub-
categorization (P . 0.05).
Table 1 Positive predictive values of US BI-RADS categories for
chest wall lesions after mastectomy
BI-RADS category n Malignant Benign PPV
4 46 11 35 23.9% (11/46)
4a 35 5 30 14.3% (5/35)
4b 8 3 5 62.5% (3/8)
4c 3 3 0 100% (3/3)
5 4 4 0 100% (4/4)
Total 50 15 35 30% (15/50)
PPV ¼ positive predictive value
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Thirty-ﬁve lesions were categorized as BI-RADS 4a
(Fig. 1). These patients had an average age of 51.5 years
(age range 34–67 years) and an average lesion size of
8 mm (range 3–19 mm). Among the 35 BI-RADS category
4a lesions, ﬁve were malignant and 30 were benign
lesions. Of these lesions, 12 (34.3%) were palpable: three
of 12 (25%) were malignant (2 IDC and 1 DCIS) and nine
(75%) were benign. The remaining 23 of 35 (65.7%)
BI-RADS 4a lesions were non-palpable. Of these, two of
23 (8.7%) were malignant (1 DCIS, 1 mucinous carcinoma),
and 21 (91.3%) were benign. In 30 patients with benign
lesions, there was no evidence of local recurrence or
distant metastasis by clinical ﬁndings or imaging study in
the follow-up period (mean time 23 months, range 13–46
months).
Eight lesions were categorized as BI-RADS 4b (Fig. 2).
These patients had an average age of 51.1 years (age range
35–66 years) and an average lesion size of 12.3 mm (range
5–21 mm). Of these lesions, ﬁve were palpable: three were
malignant (3 IDC) and two were benign. The remaining
three of eight BI-RADS 4b lesions were non-palpable, and
all were benign. All benign lesions in ﬁve patients had no
evidence of local recurrence or distant metastasis by clinical
ﬁndings or imaging study in the follow-up period (mean
time 21 months, range 14–39 months).
Three lesions were categorized as BI-RADS 4c (Fig. 3).
These patients had an average age of 51.7 years (age range
39–67 years) and an average lesion size of 12.3 mm (range
6–25 mm). Of these three masses, all were malignant
Fig. 1 A 66-year-old woman with a palpable lesion after left mastectomy. (a)
Transverse and (b) longitudinal sonography revealed a 15-mm-size complex
echoic nodule at the left chest wall. This lesion was assessed as category
4a, and US-guided core-needle biopsy was performed. Pathology results
showed fat necrosis
Fig. 2 A 43-year-old woman with a palpable lesion after right mastectomy.
Transverse sonography revealed a 12-mm-size hypoechoic nodule with
round shape, indistinct margin and nonparallel orientation at the right chest
wall. This lesion was assessed as category 4b, and US-guided fine-needle
aspiration biopsy was performed. Pathology results were positive for malig-
nancy. Surgical excision also revealed recurred invasive ductal carcinoma
Fig. 3 A 58-year-old woman with a palpable lesion after right mastectomy.
(a) Transverse and (b) longitudinal sonography revealed a 16-mm-size hypo-
echoic nodule with focal areas of speculated margin at the right chest wall.
This lesion was assessed as category 4c, and US-guided core-needle
biopsy was performed. Pathology results showed recurred invasive ductal
carcinoma in both core biopsy and surgical excision
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(2 IDC, 1 mucinous carcinoma): two were palpable and one
was non-palpable. Surgical excision was performed in all
three cases. In two patients, there was no evidence of
additional local recurrence or distant metastasis after surgi-
cal excision (mean follow-up time 35 months). In one
patient, bone metastasis was detected on whole-body PET
6 months after surgical excision of the recurred lesion.
Four lesions were categorized as BI-RADS 5 (Fig. 4).
These patients had an average age of 59 years (age range
54–64 years) and an average lesion size of 18.8 mm (range
9–28 mm). Of these lesions, all were malignant (4 IDC):
one was palpable and three were non-palpable. In one
patient, only local recurrence at the mastectomy site was
seen using imaging studies including breast US, chest CT,
abdomen CT, and whole body PET. Surgical excision was
performed in this case, and there was no evidence of
another local recurrence or distant metastasis after surgery
(follow-up time 21 months). In the remaining three patients,
distant metastasis was detected by whole body PET or CT
within 1 month, and chemotherapy was performed in
these cases.
Characteristics of 15 patients with local recurrence
at the mastectomy site
Fifteen lesions in 15 patients aged 34–64 years (mean 51.4
years) were diagnosed with local recurrence at postopera-
tive follow-up US (Table 2). Of these 15 patients, nine
(60%) had palpable lesions. The mean diameter of the
recurred lesions was 14.9 mm (range 4–28 mm). The
median interval time after mastectomy was 54.5 months
(range 6–183 months). The pathology results of the 15
lesions of local recurrence included 11 IDC, two DCIS and
two mucinous carcinomas. Four of the 15 patients (26.7%)
with local recurrence at the mastectomy site had subsequent
distant metastases during follow-up.
Discussion
A standardized lexicon for breast US was developed in 2003
by the ACR in light of the increasing use of US in clinical
practice. Many studies found the US BI-RADS lexicon and
categorization useful for predicting malignancy of a breast
mass (13–16). However, to our knowledge, the usefulness
of US BI-RADS categories for chest wall lesions at
mastectomy sites after breast surgery has not been widely
studied.
Fig. 4 A 58-year-old woman with a palpable lesion after left mastectomy. (a)
Transverse and (b) longitudinal sonography revealed a 28-mm-size hypoe-
choic nodule with irregular shape and speculated margin. This lesion was
assessed as category 5, and US-guided core-needle biopsy was performed.
Pathology results showed recurred invasive ductal carcinoma in both core
biopsy and surgical excision
Table 2 Findings in 15 patients with local recurrence after mastectomy
Patient age (years) BI-RADS Interval (months) Palpability Lesion size (mm) Pathology
39 4a 35 Non-palpable 7 Mucinous ca.
34 4a 18 Palpable 4 IDC
59 4a 29 Non-palpable 18 DCIS
55 4a 53 Palpable 8 DCIS
40 4a 17 Palpable 18 IDC
43 4b 14 Palpable 12 IDC
58 4b 95 Palpable 21 IDC
52 4b 174 Palpable 21 IDC
49 4c 12 Palpable 6 Mucinous ca.
67 4c 24 Non-palpable 25 IDC
39 4c 6 Palpable 8 IDC
60 5 75 Non-palpable 24 IDC
64 5 36 Non-palpable 9 IDC
54 5 46 Non-palpable 14 IDC
58 5 183 Palpable 28 IDC
ca. ¼ carcinoma, IDC ¼ invasive ductal carcinoma, DCIS ¼ ductal carcinoma in situ
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Rissanen et al. (17) evaluated the efﬁcacy of breast US for
the diagnosis of local breast cancer recurrence after mastect-
omy, which is the ﬁrst published report on the use of US at
the mastectomy site. The sensitivity of US was 91%, whereas
the sensitivities of clinical examination and mammography
were 79% and 45%. Mammography in a mastectomy breast
is less sensitive since it is difﬁcult to perform in this circum-
stance, and there is poor visibility of the lesions situated
deep in the muscle layer. Kanso et al. (8) assessed the
value of US at the mastectomy site according to the
BI-RADS category and found seven malignant lesions
among 11 BI-RADS category 4 lesions. However, there
was no diagnostic index of subcategorization for BI-RADS
category 4, and there were no BI-RADS 5 lesions.
In our study, the PPVs of category 4 and 5 were 14.3% in
category 4a, 62.5% in category 4b, 100% of category 4c, and
100% of category 5. This classiﬁcation showed good per-
formance and supports the feasibility of using US
BI-RADS categories to predict the local breast cancer recur-
rence at the mastectomy site. These results are consistent
with those of previous reports on PPVs of US BI-RADS cat-
egories for breast masses from untreated breasts (12, 16). Lee
et al. (16) reported that the US BI-RADS categories have a
PPV of 26% for category 4a, 83% for category 4b, 91% for
category 4c, and 96% for category 5. Yoon et al. (12) reported
that the PPVs for subcategorization of US BI-RADS 4 are
7.6% for category 4a, 37.8% for category 4b, and 81.9% for
category 4c.
The presence of palpability showed no signiﬁcant corre-
lation with malignancy in overall subcategorization in this
study. In contrast to our study, one previous study
showed that the PPV was 54.0% for palpable BI-RADS 4
lesions and 16.8% for non-palpable BI-RADS 4 lesions
(11). Baek et al. (18) also found that the clinical information
for risk factors of breast cancer and palpability can affect
the diagnostic performance and the BI-RADS ﬁnal
assessment and allow radiologists to search for subtle but
suspicious ﬁndings in the interpretation of lesions on US.
However, similar to our results, Raza et al. (19) reported
that only 9.4% of palpable BI-RADS 4 lesions were malig-
nant compared with 16.5% of non-palpable lesions.
They suggested that even when a lesion is palpable, if the
characteristics at US are benign, the likelihood is that it is
benign and may be managed without biopsy. Whether
palpable or not, overall, lesions of BI-RADS 4c and 5 were
malignant in our study. This may be because BI-RADS 4c
and 5 lesions have many suspicious US ﬁndings suggesting
malignancy. Based on this, we suggest that lesions be
managed according to US characteristics during evaluation
of local recurrence at mastectomy site, regardless of
palpability.
There are limitations to our study. First, this study only
included biopsy-proven BI-RADS category 4 and 5 lesions
at the mastectomy site. Therefore, patient selection bias
might possibly result in an overestimation of PPVs.
Furthermore, this study did not address the diagnostic
index of BI-RADS features in more benign-appearing
lesions. In clinical practice, probably benign lesions
(BI-RADS 3) may be malignant and their management is
difﬁcult, especially in patients who have undergone breast
cancer surgery. Second, we did not analyze the speciﬁc
US features that contribute to the diagnosis of local recur-
rence at the mastectomy site. Further evaluation of the US
BI-RADS lexicon, including probably benign lesions with
prospective analysis of breast lesions at the mastectomy
site would be useful to assess local recurrence in patients
with mastectomy. Third, the study population was too
small to generalize the results in all patients with
mastectomy.
In conclusion, the ACR US BI-RADS categorization of 4a,
4b, 4c, and 5 for breast lesions at the post-mastectomy site
was successful as a predictor for local recurrence. Proper
classiﬁcation according to US characteristics are helpful in
the evaluation of local recurrence at the mastectomy site,
regardless of palpability.
Conﬂict of interest: None.
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